Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-escalation Trial of TG6050 Administered by Intravenous Infusion in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT05788926 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT05788926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05788926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-escalation Trial of TG6050 Administered by Intravenous Infusion in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Transgene
Phase
Phase 1
Overall status
Terminated
Start date
April 5, 2023
Completion date
June 23, 2025
Enrollment
22 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer